SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 1,766.73 |
| Enterprise Value ($M) | 1,471.33 |
| Book Value ($M) | 554.20 |
| Book Value / Share | 6.52 |
| Price / Book | 3.19 |
| NCAV ($M) | 522.19 |
| NCAV / Share | 6.14 |
| Price / NCAV | 3.38 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.38 |
| Return on Assets (ROA) | -0.46 |
| Return on Equity (ROE) | -0.48 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 10.00 |
| Current Ratio | 10.00 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 580.88 |
| Assets | 612.88 |
| Liabilities | 58.68 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -229.95 |
| Net Income | -209.36 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -160.60 |
| Cash from Investing | 117.61 |
| Cash from Financing | 264.13 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | Kynam Capital Management, LP | 6.67 | ||
| 13G/A | Point72 Asset Management, L.P. | 3.30 | -19.48 | |
| 13G/A | Avidity Partners Management LP | 4.70 | -41.20 | |
| 13G | Vanguard Group Inc | 5.11 | ||
| 13G/A | Wellington Management Group Llp | 8.94 | -4.99 | |
| 13G/A | State Street Corp | 5.91 | 37.49 | |
| 13G/A | BlackRock Inc. | 8.30 | 61.20 | |
| 13G/A | Frazier Life Sciences Public Fund, L.P. | 0.00 | -100.00 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| 84,826,632 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| Form 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 35,882 | 239,963 | 14.95 | |
| 52,904 | 366,999 | 14.42 | |
| 46,475 | 318,680 | 14.58 | |
| 107,673 | 434,404 | 24.79 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| SGMO – Sangamo Therapeutics, Inc. | SLDB – Solid Biosciences Inc. |
| SLRN – Acelyrin, Inc. | SOPH – SOPHiA GENETICS SA |
| SPRB – Spruce Biosciences, Inc. |
Financial data and stock pages provided by
Fintel.io